Loxo Oncology Культура компании

Mr. Jacob S. Van Naarden, also known as Jake, has been Chief Business Officer at Loxo Oncology, Inc. since December 2015 and served as a Vice President of Corporate Development and Strategy since July 2014. Mr. Van Naarden served as an Analyst at Aisling Capital LLC. Previously, he was an Analyst in the Healthcare Group of Goldman Sachs's Investment Banking Division, where he worked closely with management of companies across the worldwide healthcare industry, primarily in pharmaceuticals and biotechnology, in the evaluation and execution of acquisitions, financings and corporate strategy. Mr. Van Naarden received an A.B. from Princeton University, awarded Phi Beta Kappa and magna cum laude, in molecular biology.

Ms. Sara Slifka has been Vice President of Business Operations & Program Management at Loxo Oncology, Inc. since April 14, 2017. Ms. Slifka served as Executive Director of Business Operations and Program Management at Loxo Oncology, Inc. until April 14, 2017 and served as its senior Director of Operations. Ms. Slifka served as a Vice President in Equity Research at Morgan Stanley covering the biotech sector. Ms. Slifka analyzed small and large cap biotechnology companies from a financial, clinical, regulatory and commercial perspective. She served as an Associate of Morgan Stanley, Research Division. Ms. Slifka received her A.B. degree from Princeton University.

Dr. Lori Anne Kunkel, M.D., serves as Principal at D2D, LLC. Dr. Kunkel serves as a Consultant at Loxo Oncology, Inc. Dr. Kunkel has extensive experience in developing and commercializing oncologic and immunologic therapies, with over 20 years of executive responsibilities in industry including clinical, regulatory, medical affairs and licensing. She served as an Executive Officer of Pharmacyclics LLC (alternate name, Pharmacyclics Inc.) since July 9, 2013 and served as its Chief Medical Officer from December 2012 to July 9, 2013. Dr. Kunkel served as the Chief Medical officer of Onyx Therapeutics, Inc., since April 26, 2007. She served as the Chief Medical Officer at Syndax and Loxo Oncology from October 2013 to October 2014. Dr. Kunkel served as the Chief Medical Officer at ACT Biotech, Inc. She served as Acting Chief Medical Officer of Curis, Inc. She served as CMO at Proteolix, acquired by Onyx, where she oversaw the clinical development of KYPROLIS. She served as Vice President of Clinical Development for Xencor, Inc. from 2005 to 2007. Dr. Kunkel was responsible for clinical and clinical/regulatory strategies for the development of Xencor's products. She oversaw planning and clinical project management from late-stage discovery to the clinic in support of safe and effective use of products during clinical trials. Dr. Kunkel held senior positions at ACT Therapeutics, Syndax, Genitope Corporation, Genentech Inc., Chiron Corporation (now Novartis), Salmedics (acquired by Celgene), Stemcentrx, Inc., Baxter Immunotherapy and was an independent Clinical Oncology and Immunology Consultant for several biotechnology companies, offering strategic clinical, regulatory and technical advices. She serves as the Chair of Advisory Board at MedCision, Inc. She has been an Advisory Board Chair at BioCision, LLC since February 8, 2016. She has been a Director at Loxo Oncology, Inc. since October 23, 2014 and Tocagen Inc. since September 10, 2015. She serves as a Director of Maverick Therapeutics. She serves as a Member of Advisory Board at BioCision, LLC and also served as its Member of the Advisory Board since September 2010. She has been Member of Clinical and Scientific Advisory Board at Verastem, Inc. since January 19, 2017. She has been Director of Curis, Inc. since November 11, 2016. She serves on the Board of Directors at Harpoon Therapeutics and Amphivena Therapeutics. Dr. Kunkel served as an Assistant Professor in the Division of Hematology/Oncology Bone Marrow Transplant Division at the University of California, Los Angeles. She is board certified in internal medicine, hematology and oncology. Dr. Kunkel completed her training in Internal Medicine at the Baylor College of Medicine where she also served as the Chief Medical Resident. She completed her clinical fellowship training in Hematology at the University of California and finished an Oncology fellowship at the University of California, Los Angeles. Dr. Kunkel received her M.D. at the University of Southern California and completed her internship and residency in Internal Medicine at Baylor College of Medicine. Dr. Kunkel received a B.A. from The University of California, San Diego (UCSD).

Ms. Jennifer Burstein, M.B.A. CPA, serves as Senior Vice President of Finance and Principal Financial Officer of Loxo Oncology, Inc. She served as Vice President of Finance of Loxo Oncology, Inc. since May 1, 2015. Ms. Burstein served as Vice President of Finance at Acorda Therapeutics, Inc. from July 2010 to April 2015. Ms. Burstein served as an Executive Director and Director of Finance since joining Acorda in 2006. Ms. Burstein was responsible for all finance related activities including SEC filings, financings, SOX implementation and monitoring, financial closes, collaboration accounting, budgeting and Ampyra launch-related accounting issues. Prior to joining Acorda, from 2002 to 2006, she was with Eyetech Pharmaceuticals, Inc., a public biotechnology company. Ms. Burstein held several positions of increasing responsibility for Eyetech Pharmaceuticals including Senior Director of Accounting. She has a CPA license in New York. Ms. Burstein received her B.S. in Business Administration and M.B.A. in Accounting from the State University of New York at Buffalo.

Sara Shulman serves as the Vice President, Business Operations and Program Management of LOXO Oncology, Inc.. Sara started at LOXO Oncology, Inc. in January of 2017. Sara currently resides in Greater New York City Area.

Jennifer Kronick serves as the Vice President, Human Resources/Law of LOXO Oncology, Inc.. Jennifer started at LOXO Oncology, Inc. in January of 2018. Jennifer currently resides in Greater New York City Area.

Katie Cairati serves as the Executive Director Global Regulatory Affairs of LOXO Oncology, Inc.. Katie started at LOXO Oncology, Inc. in March of 2016. Katie currently resides in San Francisco Bay Area.